A randomized, double-blind, placebo-controlled trial was performed to evaluate the efficacy and safety of AST-120 in nonconstipating IBS. 115 patients were randomly allocated to receive AST-120 (2 g three times daily) or placebo. AST-120 was found to be safe and well-tolerated. Although AST-120 reduced pain and bloating, these beneficial effects might be limited in duration. Further studies of this novel agent are warranted.
ORIGINAL RESEARCH PAPER
Tack, J. F. et al. Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome—a double-blind, placebo-controlled study. Aliment. Pharmacol. Ther. doi: 10.1111/j.1365-2036.2011.04818.x
Rights and permissions
About this article
Cite this article
AST-120 for the treatment of nonconstipating IBS. Nat Rev Gastroenterol Hepatol 8, 602 (2011). https://doi.org/10.1038/nrgastro.2011.183
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2011.183
